2026-02-21
Gut Microbiome and Probiotics in Aging: Diversity Decline, Leaky Gut, and Evidence-Based Interventions
The gut microbiome undergoes progressive diversity loss with age — a pattern linked to increased intestinal permeability, systemic inflammation, and reduced short-chain fatty acid production. Dietary fiber, fermented foods, and targeted probiotics have the best evidence for reversing these changes.
2026-02-21
Lactobacillus acidophilus: Gut Health, Immune Modulation, and Strain-Specific Evidence
Lactobacillus acidophilus is one of the most studied probiotic species, with evidence spanning IBS symptom relief, immune modulation, and cholesterol reduction. Strain specificity matters enormously — not all L. acidophilus products produce identical effects.
2026-02-20
Inulin and Prebiotic Fiber: Microbiome Diversity, GLP-1, and Metabolic Benefits
Inulin-type fructans selectively feed Bifidobacterium and Lactobacillus species, raising SCFA production. Clinical trials show dose-dependent improvements in glycemic control, lipid profiles, and gut transit. Effective doses (10–20 g/day) frequently cause transient gas — gradual titration is essential.
2026-02-13
The Microbiome-Longevity Connection: Centenarian Studies, Gut Diversity, and Prebiotic Strategy
Centenarian microbiome studies consistently show higher diversity, more short-chain fatty acid producers, and distinct bacterial profiles compared to age-matched controls. Dietary fiber remains the strongest intervention for diversity. This article maps what the longevity-microbiome evidence shows and what remains speculative.
2026-02-07
Acarbose and Longevity: ITP Lifespan Data, Postprandial Glucose Control, and Gut Microbiome Effects
Acarbose extended lifespan in male mice more than any other drug in the ITP study. Its alpha-glucosidase inhibition reduces postprandial glucose spikes and feeds colonic bacteria, improving microbiome composition. Human longevity use is off-label and based on mechanistic extrapolation.